kawasaki
diseas
kd
acut
selflimit
inflammatori
disord
associ
vascul
affect
predominantli
mediums
arteri
particularli
coronari
arteri
develop
countri
kd
commonest
caus
acquir
heart
diseas
childhood
aetiolog
kd
remain
unknown
current
believ
one
yet
unidentifi
infecti
agent
induc
intens
inflammatori
host
respons
genet
suscept
individu
genet
studi
identifi
sever
suscept
gene
kd
sequela
differ
ethnic
popul
includ
itpkc
well
gene
influenc
respons
intraven
immunoglobulin
ivig
aneurysm
format
transform
growth
factor
tgf
pathway
gene
ivig
aspirin
effect
therapeut
recent
clinic
trial
metaanalys
demonstr
addit
corticosteroid
ivig
benefici
prevent
coronari
arteri
aneurysm
caa
sever
case
highest
risk
ivig
resist
outsid
japan
howev
clinic
score
predict
ivig
resist
perform
suboptim
furthermor
evid
base
provid
clear
guidanc
corticosteroid
regimen
effect
therapi
includ
could
also
role
ivigresist
kd
irrespect
caveat
clear
therapi
reduc
inflamm
acut
kd
improv
outcom
paper
summaris
recent
advanc
understand
kd
pathogenesi
therapeut
provid
approach
manag
kd
patient
uk
light
advanc
kawasaki
diseas
kd
affect
children
age
year
uk
commonest
caus
acquir
heart
diseas
children
develop
countri
kd
probabl
repres
aberr
inflammatori
host
respons
one
yet
unidentifi
pathogen
occur
genet
predispos
individu
kd
associ
system
vascul
particularli
affect
coronari
arteri
caus
coronari
arteri
aneurysm
caa
untreat
patient
untreat
case
die
result
coronari
vascul
view
frequenc
sever
coronari
arteri
complic
intens
interest
treatment
reduc
risk
caa
kd
also
potenti
import
caus
longterm
cardiac
diseas
adult
life
notabl
children
kd
advanc
adulthood
studi
need
improv
understand
longterm
cardiac
sequela
optimis
therapi
childhood
minimis
risk
adulthood
ensur
continu
qualiti
evidencebas
care
kd
patient
transit
adult
servic
purpos
articl
summaris
recent
advanc
understand
pathogenesi
treatment
kd
provid
approach
manag
kd
uk
light
advanc
updat
guidelin
base
evid
metaanalys
randomis
control
trial
rct
highlight
area
practic
evid
remain
weak
last
suggest
futur
research
outlin
kd
second
commonest
vasculit
ill
childhood
henoch
purpura
commonest
caus
acquir
heart
diseas
children
develop
countri
diseas
worldwid
distribut
male
preponder
ethnic
bia
toward
asian
children
particularli
east
asian
season
occasion
epidem
incid
japan
children
younger
year
wherea
usa
uk
variat
awar
among
clinician
kd
differ
countri
region
referr
pattern
may
contribut
epidemiolog
differ
howev
major
differ
like
result
ethnic
racial
differ
suscept
exposur
presum
pathogen
approxim
children
kd
younger
year
age
peak
age
incid
month
patient
age
less
month
year
encount
less
commonli
increas
risk
caa
format
aetiolog
kd
remain
unknown
pronounc
season
cluster
kd
case
led
hunt
infecti
agent
caus
far
howev
singl
agent
consist
identifi
mani
publish
report
implic
number
bacteri
viral
pathogen
includ
retrovirus
epsteinbarr
viru
coronaviru
propionibacterium
acn
staphylococc
streptococc
superantigen
unidentifi
viru
particl
infecti
trigger
kd
date
singl
pathogen
confirm
subsequ
studi
debat
regard
infecti
caus
kd
centr
around
mechan
immun
activ
convent
antigen
versu
superantigen
sag
superantigen
seem
plausibl
caus
disord
view
clinic
immunolog
similar
kd
staphylococc
streptococc
superantigenmedi
disord
sever
studi
present
open
access
scan
access
free
content
evid
support
superantigentrigg
process
other
confirm
associ
one
explan
inconsist
find
kd
trigger
rang
differ
superantigen
anim
studi
suggest
possibl
superantigen
tolllik
receptor
agonist
may
need
act
synergist
superantigen
sag
mediat
process
report
rowley
et
al
three
fatal
case
kd
iga
plasma
cell
infiltr
vascular
wall
acut
phase
ill
observ
examin
clonal
iga
respons
use
revers
transcriptas
rt
pcr
lesion
vascular
tissu
research
observ
iga
respons
oligoclon
suggest
convent
antigen
process
rather
superantigenicdriven
one
although
uncertainti
remain
regard
mechan
initi
immun
activ
author
believ
one
potenti
ubiquit
infecti
agent
produc
deleteri
host
respons
genet
suscept
subject
genet
genet
contribut
risk
kd
suggest
much
higher
risk
diseas
asian
children
particularli
japanes
korean
persist
patient
ethnic
migrat
countri
observ
increas
rel
risk
sibl
index
case
compar
gener
popul
twin
studi
well
document
multicas
famili
mani
candid
gene
previous
suggest
either
suscept
gene
develop
kd
increas
risk
caa
summaris
elsewher
earlier
studi
howev
fail
identifi
definit
genet
associ
emphasis
difficulti
candid
gene
approach
diseas
pathogenesi
poorli
understood
contrast
candid
gene
approach
genomewid
associ
studi
gwa
advantag
identifi
diseaseassoci
gene
without
requir
prior
knowledg
mechan
involv
number
gwa
kd
publish
far
studi
sever
singl
nucleotid
polymorph
snp
associ
suscept
kd
includ
itpkc
gene
region
near
tabl
furthermor
gene
associ
nonrespons
intraven
immunoglobulin
ivig
risk
caa
includ
gene
signal
pathway
like
mani
genet
factor
yet
identifi
gwa
methodolog
far
identifi
signific
associ
whole
exom
sequenc
studi
appli
individu
kd
case
extrem
phenotyp
giant
caa
could
clarifi
contribut
rarer
genet
variant
extrem
case
thu
studi
genet
contribut
kd
remain
intens
area
research
worldwid
still
much
work
progress
diagnost
test
kd
thu
diagnosi
rest
combin
clinic
criteria
laboratori
find
tabl
diagnosi
establish
accord
diagnost
guidelin
japan
kd
research
committe
five
six
criteria
tabl
present
north
american
recommend
diagnosi
similar
except
taiwanes
japanes
l
express
surfac
tcell
platelet
engag
express
surfac
antigenpres
cell
endotheli
cell
transduc
signal
relat
cell
activ
develop
elev
express
l
acutephas
kd
significantli
higher
express
kd
patient
caa
report
caa
coronari
arteri
aneurysm
nfat
nuclear
factor
activ
cell
fever
mandatori
criterion
four
remain
five
criteria
requir
establish
diagnosi
howev
addit
patient
fulfil
criteria
complet
kd
mani
patient
clinic
featur
kd
patient
may
still
risk
caa
diagnosi
incomplet
kd
case
depend
high
level
suspicion
children
present
kd
featur
evid
system
inflamm
elev
creactiv
protein
crp
erythrocyt
sediment
rate
esr
leucocytosi
earli
echocardiographi
may
reveal
evid
coronari
vascul
confirm
diagnosi
kd
patient
group
neg
echocardiogram
exclud
diagnosi
kd
addit
diagnost
challeng
incomplet
case
requir
within
exist
diagnost
criterion
fever
greater
day
may
also
lead
delay
treatment
durat
fever
histor
import
standardis
case
definit
clinician
delay
make
diagnosi
kd
institut
treatment
see
diagnost
criteria
kd
present
day
fever
caa
coronari
dilat
present
evid
persist
elev
inflammatori
marker
explan
patient
remain
clinic
suspicion
kd
recommend
seek
earli
expert
advic
case
irrit
import
sign
nearli
alway
present
although
interestingli
includ
one
diagnost
criteria
exact
mechan
irrit
unclear
may
relat
presenc
asept
mening
anoth
import
clinic
sign
develop
erythema
indur
site
previou
bacillu
bcg
immunis
mechan
clinic
sign
believ
due
crossreact
cell
kd
patient
specif
epitop
mycobacteri
human
heatshock
protein
diagnost
criteria
may
present
sequenti
socal
incomplet
case
evolv
time
complet
case
thu
diagnosi
kd
must
consid
child
febril
exanthemat
ill
evid
inflamm
particularli
persist
longer
day
rel
common
clinic
find
kd
includ
arthriti
asept
mening
pneumon
uveiti
gastroenter
meatiti
dysuria
otiti
rel
uncommon
abnorm
includ
hydrop
gallbladd
gastrointestin
ischaemia
jaundic
cranial
nerv
palsi
renal
involv
pyuria
proteinuria
tubular
disturb
tubulointerstiti
nephriti
renal
failur
petechi
rash
shock
syndrom
febril
convuls
encephalopathi
ataxia
addit
rare
complic
kd
includ
macrophag
activ
syndrom
secondari
haemophagocyt
lymphohistiocytosi
syndrom
inappropri
antidiuret
hormon
secret
result
hyponatraemia
main
site
clinic
import
vascular
involv
coronari
arteri
although
vessel
axillari
arteri
involv
caa
occur
untreat
case
addit
cardiac
featur
signific
proport
includ
pericardi
effus
electrocardiograph
abnorm
pericard
myocard
valvular
incompet
cardiac
failur
myocardi
infarct
system
arteri
injuri
major
limb
arteri
renal
viscer
vessel
occur
rare
seen
absenc
caa
laboratori
find
kd
invari
associ
inflammatori
process
elev
esr
crp
white
cell
count
absenc
signific
inflamm
diagnosi
kd
unlik
inflammatori
marker
may
abnorm
first
present
repeat
blood
test
undertaken
diagnost
uncertainti
thrombocytosi
occur
toward
end
second
week
ill
therefor
may
help
diagnost
earli
stage
acut
thrombocytopenia
lownorm
platelet
count
may
occur
may
associ
poorer
prognosi
see
liver
function
may
derang
patient
present
jaundic
elev
transaminas
hypoalbuminaemia
common
steril
pyuria
cerebrospin
fluid
csf
pleocytosi
predominantli
lymphocyt
repres
asept
mening
also
occur
predict
ivig
resistancehigh
caa
risk
sever
score
system
develop
identifi
children
highest
risk
ivig
resist
henc
highest
risk
develop
caa
tabl
kobayashi
et
al
develop
model
predict
unrespons
ivig
japanes
children
kd
use
defin
sever
case
pivot
alt
alanin
aminotransferas
ast
aspart
aminotransferas
crp
creactiv
protein
ivig
intraven
immunoglobulin
clinic
trial
corticosteroid
see
ivig
resist
known
strong
risk
factor
develop
caa
kobayashi
egami
sano
score
test
usa
studi
demonstr
compar
high
specif
predict
ivig
nonrespons
nonjapanes
patient
low
sensit
clinic
implic
risk
score
posit
nonjapanes
patient
eg
kobayashi
score
ivig
resist
like
howev
neg
score
reliabl
exclud
ivig
resist
attempt
develop
sensit
specif
score
patient
outsid
japan
thu
far
unsuccess
earli
recognit
treatment
kd
aspirin
ivig
shown
unequivoc
randomis
control
trial
metaanalysi
reduc
occurr
caa
two
gkg
ivig
optim
dose
usual
given
singl
infus
metaanalysi
randomis
control
trial
compar
divid
lower
dose
ivig
mgkgday
four
consecut
day
versu
singl
infus
highdos
ivig
gkg
h
shown
even
though
regimen
benefit
singledos
regimen
greater
therapeut
effect
prevent
caa
aspirin
metaanalysi
compar
antiinflammatori
dose
aspirin
mgkgday
highdos
aspirin
mgkgday
combin
ivig
found
signific
differ
incid
caa
group
current
aspirin
dose
mgkgday
recommend
acut
phase
ill
may
better
toler
higher
dose
term
gastrointestin
side
effect
dose
reduc
antiplatelet
dose
mgkg
fever
inflamm
subsid
corticosteroid
primari
treatment
sever
kd
ivig
resist
occur
case
patient
increas
risk
develop
caa
unless
receiv
addit
treatment
recent
find
publish
rais
studi
select
patient
high
risk
ivig
nonrespons
emphasis
point
treatment
control
arm
ivig
aspirin
still
associ
caa
complic
rate
corticosteroid
effect
treatment
form
vascul
earli
retrospect
analys
suggest
corticosteroid
associ
increas
risk
caa
howev
almost
certainli
reflect
select
bia
sickest
patient
receiv
steroid
clinic
trial
evalu
use
corticosteroid
plu
ivig
produc
seemingli
confus
result
chen
et
al
recent
report
metaanalysi
compar
frequenc
caa
patient
treat
ivig
plu
corticosteroid
ivig
alon
primari
treatment
kd
follow
standard
guidelin
conduct
metaanalys
use
defin
criteria
trial
qualiti
assess
includ
evalu
criteria
diagnosi
studi
design
follow
blind
identifi
nine
clinic
studi
meet
qualiti
criteria
involv
patient
six
nine
prospect
rct
two
nonrandomis
control
studi
one
retrospect
report
patient
includ
receiv
ivigcorticosteroid
ivig
alon
found
significantli
fewer
patient
receiv
ivigcorticosteroid
develop
caa
receiv
ivig
alon
vs
ci
benefit
found
sever
subgroup
analys
includ
six
prospect
rct
studi
use
prednisolon
intraven
methylprednisolon
found
signific
differ
frequenc
sever
advers
event
steroid
nonsteroid
treatment
group
chen
metaanalysi
provid
convinc
evid
steroid
combin
ivig
initi
treatment
reduc
overal
risk
caa
sever
kd
howev
neither
meta
analysi
rais
studi
provid
clear
answer
whether
children
uk
treat
corticosteroid
dose
durat
rout
corticosteroid
use
heterogen
corticosteroid
dose
publish
trial
import
consider
translat
result
chen
metaanalysi
clinic
practic
differ
corticosteroid
regimen
use
trial
illustr
two
methodolog
strongest
studi
american
paediatr
heart
network
studi
recent
report
japanes
rais
studi
consid
detail
american
studi
evalu
use
intraven
methylprednisolon
mgkg
given
singl
dose
unselect
patient
kd
contrast
rais
evalu
lowerdos
mgkg
intraven
prednisolon
given
day
fever
settl
convert
oral
prednisolon
subsequ
taper
day
crp
normalis
moreov
patient
includ
rais
high
risk
ivig
resist
base
kobayashi
score
perhap
unsurprisingli
two
studi
produc
conflict
result
steroid
confer
signific
benefit
japanes
rais
studi
lack
overal
benefit
american
studi
second
seven
nine
studi
metaanalysi
undertaken
japan
two
usa
result
may
applic
outsid
japan
concern
kd
japan
may
behav
differ
diseas
nonjapanes
popul
highlight
failur
kobayashi
score
use
predict
ivig
nonrespons
japan
accur
predict
nonrespons
ivig
usa
metaanalysi
may
say
benefici
effect
steroid
japanes
patient
meet
criteria
predict
ivig
resist
overal
benefit
unselect
patient
third
metaanalysi
reveal
increas
sever
advers
event
associ
corticosteroid
use
total
number
patient
receiv
steroid
paediatrician
routin
use
corticosteroid
treatment
system
inflammatori
diseas
probabl
comfort
modest
dose
regimen
prednisolon
wean
week
truli
spare
children
potenti
lifelong
cardiac
sequela
although
vigil
followup
presenc
corticosteroidrel
complic
hypertens
behaviour
chang
secondari
infect
hyperglycaemia
bone
necrosi
requir
patient
kd
respond
aspirin
ivig
caa
commonli
seen
fail
respond
ivig
urgent
need
mean
predict
ivig
resist
corticosteroid
includ
primari
treatment
select
patient
risk
ivig
nonrespons
howev
kobayashi
score
use
japanes
investig
low
sensit
good
specif
tabl
predict
ivig
nonrespons
studi
usa
therefor
low
kobayashi
score
reliabl
exclud
ivig
resist
caveat
mind
propos
pragmat
treatment
approach
base
current
data
advoc
research
provid
evid
base
current
lack
suggest
corticosteroid
consid
patient
alreadi
declar
ivigresist
ongo
fever
andor
persist
inflamm
clinic
sign
h
receiv
ivig
singl
dose
gkg
patient
featur
sever
diseas
therefor
greatest
likelihood
develop
caa
absenc
valid
risk
score
outsid
japan
suggest
patient
includ
young
marker
sever
inflamm
includ
persist
elev
crp
despit
ivig
liver
dysfunct
hypoalbuminaemia
anaemia
small
group
develop
featur
haemophagocyt
lymphohistiocytosi
hlh
andor
shock
patient
alreadi
evolv
coronari
andor
peripher
aneurysm
ongo
inflamm
present
increasingli
recognis
echocardiograph
studi
perform
first
week
kd
may
alreadi
show
vessel
abnorm
includ
bright
suggest
inflamm
dilat
compar
agerel
normal
rang
andor
extracoronari
manifest
includ
mitral
regurgit
pericardi
effus
patient
featur
may
also
greater
risk
caa
therefor
may
requir
corticosteroid
corticosteroid
regimen
use
chen
metaanalysi
provid
us
evid
base
optim
corticosteroid
dosedur
studi
includ
intraven
prepar
equival
mgkg
prednisolon
day
crp
normalis
follow
oral
prednisolon
wean
week
seem
logic
howev
absenc
robust
evid
base
flexibl
steroid
regimen
ultim
use
individu
patient
recommend
ultim
determin
treat
clinician
updat
guidelin
provid
two
suggest
regimen
figur
second
dose
ivig
given
patient
fail
respond
initi
dose
patient
shown
complet
respons
suggest
second
dose
ivig
given
time
commenc
steroid
alreadi
commenc
sign
sever
diseas
see
second
dose
may
benefici
littl
respons
first
dose
vigil
followup
presenc
corticosteroidrel
complic
hypertens
secondari
infect
hyperglycaemia
bone
necrosi
requir
emerg
anim
data
case
report
suggest
role
antitumour
necrosi
factor
tnf
therapi
treatment
kd
serum
elev
kd
patient
higher
level
correl
develop
caa
commonli
use
agent
infliximab
chimer
murin
human
monoclon
antibodi
specif
bind
one
retrospect
studi
children
ivigresist
kd
infliximab
use
success
abrupt
defervesc
febril
patient
infus
reaction
burn
et
al
report
phase
clinic
trial
includ
patient
receiv
infliximab
demonstr
treatment
safe
well
toler
patient
resist
ivig
respons
therapi
cessat
fever
occur
patient
crp
level
elev
one
patient
infliximab
infus
level
lower
follow
infus
patient
remeasur
within
h
treatment
infus
reaction
infliximab
complic
attribut
infliximab
administr
patient
recent
us
retrospect
review
ivigresist
patient
treat
either
ivig
infliximab
demonstr
patient
treat
infliximab
fewer
day
fever
shorter
hospitalis
similar
coronari
arteri
outcom
etanercept
solubl
receptor
altern
tnf
antagonist
report
safe
well
toler
children
kd
given
dose
mg
per
kilogram
weekli
three
dose
may
benefici
recent
multicentr
studi
usa
compar
ivig
aspirin
ivigaspirin
plu
infliximab
initi
therapi
unselect
group
kd
patient
complet
show
signific
reduct
caa
although
trial
underpow
endpoint
howev
faster
resolut
acutephas
respons
infliximab
group
burn
jc
et
al
person
commun
manuscript
submit
thu
consid
patient
ivigresist
kd
studi
requir
role
firstlin
therapi
immunosuppress
agent
ciclosporin
cyclophosphamid
methotrex
plasma
exchang
occasion
use
treat
patient
respond
ivig
steroid
genomewid
associ
studi
identifi
polymorph
itpkc
neg
regul
tcell
activ
cell
signal
pathway
gene
associ
kd
suscept
ivig
resist
increas
risk
caa
asian
us
children
suggest
calcineurin
inhibitor
ciclosporin
may
applic
treatment
kd
initi
report
need
temper
knowledg
calcineurin
inhibitor
also
toxic
endothelium
exampl
diseas
recommend
avoid
cerebr
vascul
sinc
concern
class
drug
may
exacerb
vasculit
complic
scenario
use
agent
recommend
routin
consid
casebycas
basi
consult
specialist
unit
convalesc
phase
condit
aneurysm
persist
antiplatelet
therapi
form
lowdos
aspirin
mgkg
continu
longterm
aneurysm
resolv
clopidogrel
altern
antiplatelet
agent
could
consid
presenc
giant
aneurysm
mm
warfarin
recommend
addit
aspirin
heparin
administ
initi
least
h
stop
warfarin
commenc
intern
normalis
ratio
inr
stabl
two
three
avoid
paradox
thrombosi
due
protein
c
deplet
may
occur
warfarin
treatment
start
thrombosi
occur
thrombolyt
therapi
may
indic
expert
advic
must
sought
patient
may
requir
coronari
angioplasti
revascularis
procedur
ischaem
symptom
aris
evid
obstruct
occur
formal
cathet
coronari
arteriographi
consid
possibl
defer
first
month
acut
ill
avoid
proceduralrel
myocardi
infarct
particular
concern
coronari
endothelium
still
activ
inflam
recommend
regard
time
immunis
kd
remain
unchang
guidelin
immunis
vaccin
defer
least
month
follow
episod
kd
treat
ivig
mainli
due
potenti
lack
effect
live
vaccin
follow
ivig
due
potenti
vaccin
induc
potenti
detriment
immun
activ
convalesc
phase
kd
evid
latter
recommend
anecdot
thereaft
vaccin
administ
recommend
nation
schedul
patient
requir
longterm
aspirin
persist
caa
consid
immunis
varicella
zoster
viru
vzv
vaccin
view
associ
vzv
aspirin
rey
syndrom
prognosi
larg
determin
cardiac
sequela
kd
outlook
kd
patient
normal
coronari
echocardiograph
find
mild
dilat
assess
week
onset
gener
good
howev
patient
persist
coronari
arteri
dilat
aneurysm
risk
coronari
arteri
stenosi
thrombosi
british
paediatr
surveil
unit
bpsu
studi
indic
mortal
rate
uk
kd
time
write
repeat
bpsu
survey
ongo
figur
recommend
clinic
guidelin
manag
kawasaki
diseas
uk
sinc
risk
score
ivig
resist
perform
suboptim
nonjapanes
patient
tabl
recommend
use
defin
high
risk
definit
clinician
may
howev
choos
consid
clinic
laboratori
paramet
list
identifi
high
risk
patient
kobayashi
risk
score
posit
nonjapanes
patient
eg
ivig
resist
like
howev
score
reliabl
exclud
ivig
resist
aim
treatment
switch
inflammatori
process
damag
coronari
arteri
rapidli
possibl
absenc
strong
evid
base
favour
specif
corticosteroid
regimen
two
suggest
corticosteroid
regimen
highrisk
case
provid
clinician
choos
low
dose
aspirin
also
recommend
avoid
concomit
use
nonsteroid
antiinflammatori
drug
nsaid
interfer
antiplatelet
effect
low
dose
aspirin
treatment
commenc
day
fever
sepsi
exclud
treatment
also
given
present
day
fever
onset
sign
persist
inflamm
kobayashi
risk
score
point
refer
paediatr
cardiologist
specif
intervent
positron
emiss
tomographi
pet
scan
addit
calcium
channel
blocker
therapi
coronari
angioplasti
discret
paediatr
cardiologist
immunomodul
may
includ
ciclosporin
infant
z
score
intern
coronari
arteri
diamet
base
montreal
norm
data
http
provid
uptod
outcom
data
uk
angiograph
resolut
year
onset
diseas
observ
vessel
coronari
aneurysm
giant
aneurysm
never
resolv
complet
studi
explor
longterm
outcom
cohort
patient
kd
enrol
mortal
rate
patient
without
cardiac
sequela
acut
phase
diseas
femal
patient
sequela
differ
normal
popul
allcaus
mortal
rate
male
cardiac
sequela
howev
time
higher
normal
popul
patient
kd
undergo
echocardiographi
diagnosi
week
onset
diseas
intermedi
echocardiogram
day
diseas
onset
perform
initi
echo
normal
diseas
activ
arrest
echocardiographi
perform
least
weekli
aneurysm
detect
initi
echocardiographi
echo
ongo
activ
inflamm
monitor
aneurysm
size
progress
develop
thrombu
format
longterm
aspirin
mgkgday
recommend
persist
aneurysm
echocardiographi
discontinu
aneurysm
resolv
depend
size
aneurysm
electrocardiographi
echocardiographi
perform
monthli
recommend
patient
persist
aneurysm
beyond
week
longterm
cardiovascular
followup
adult
life
requir
may
echocardiograph
resolut
aneurysm
time
due
vessel
remodel
fibrosi
prolifer
subendotheli
tissu
lesion
may
remain
thicken
abnorm
even
echocardiograph
resolut
prognosi
guard
giant
aneurysm
recent
singlecentr
studi
describ
cohort
japanes
kd
patient
giant
aneurysm
mm
intern
diamet
surviv
rate
cumul
intervent
rate
cathet
surgic
year
postacut
kd
develop
myocardi
infarct
patient
histori
kd
coronari
aneurysm
reach
young
adulthood
acut
mycocardi
infarct
due
thrombosi
aneurysm
due
progress
arteri
stenosi
aneurysm
remodel
increas
concern
note
percutan
translumin
coronari
angioplasti
associ
high
rate
restenosi
occlus
kd
patient
thu
rotat
ablat
bypass
surgeri
may
advis
altern
procedur
intravascular
ultrasound
ivu
play
import
role
intervent
patient
histori
kd
help
determin
extent
arteri
calcif
evalu
intervent
result
ensur
proper
stent
size
placement
coronari
arteri
bypass
graft
cabg
surgeri
also
use
patient
kd
sever
obstruct
lesion
result
gener
good
especi
intern
thorac
arteri
use
set
giant
coronari
aneurysm
without
signific
obstruct
cabg
may
ineffect
prevent
myocardi
infarct
graft
patenc
may
compromis
compet
flow
nativ
coronari
arteri
recommend
longterm
cardiac
manag
detail
review
area
beyond
scope
articl
statement
american
heart
associ
committe
rheumat
fever
endocard
kd
publish
provid
detail
guidanc
stratif
kd
patient
accord
rel
risk
myocardi
ischaemia
risklevel
categori
summaris
tabl
stratif
allow
patient
manag
individualis
respect
medic
therapi
reduc
risk
thrombosi
physic
activ
frequenc
clinic
followup
diagnost
test
indic
cardiac
catheteris
coronari
ct
mr
angiographi
stress
echocardiographi
consid
safe
cardiologist
perform
patient
persist
structur
abnorm
coronari
arteri
evid
induc
ischaemia
invas
angiographi
indic
patient
biannual
followup
aggress
manag
tradit
cardiovascular
risk
factor
also
recommend
patient
ct
coronari
arteri
calcium
score
link
mortal
atherosclerosi
suggest
imag
modal
could
import
role
late
followup
kd
adolesc
young
adult
may
develop
coronari
calcif
detect
year
acut
kd
episod
promis
potenti
mean
stratifi
patient
longterm
followup
yet
known
kd
exactli
coronari
arteri
score
relat
late
morbid
mortal
time
write
longterm
followup
studi
prematur
atherosclerosisl
kd
vasculopathi
ongo
uk
anticip
studi
help
guid
clinician
regard
longterm
followup
kd
sinc
recognit
ivig
could
reduc
morbid
mortal
kd
treatment
condit
larg
protocol
driven
although
author
differ
advocaci
varieti
treatment
protocol
like
success
therapeut
intervent
kd
due
modul
caus
andor
propag
inflamm
reevalu
current
prescript
approach
manag
kd
light
publish
literatur
ad
corticosteroid
primari
therapi
sever
ivig
unrespons
case
suggest
role
system
inflamm
persist
despit
ivig
aspirin
corticosteroid
repeat
protocoldriven
administr
ivig
patient
littl
evid
clinic
andor
laboratori
improv
may
detriment
treatment
corticosteroid
andor
consid
uncheck
inflamm
damag
vasculatur
kd
acutephas
respons
particularli
crp
combin
clinic
respons
use
assess
efficaci
intervent
minimum
three
echocardiogram
perform
first
week
ill
justif
patient
albeit
minor
develop
caa
first
week
ill
earli
detect
prompt
aggress
primari
manag
earli
echocardiographi
first
week
may
detect
extracoronari
manifest
mitral
regurgit
pericardi
effus
may
associ
increas
risk
caa
earli
detect
caa
progress
andor
develop
thrombu
might
detect
could
result
intensif
antiinflammatori
andor
addit
anticoagul
therapi
philosophi
mind
light
therapeut
advanc
discuss
present
updat
clinic
guidelin
manag
kd
uk
figur
therapeut
uncertainti
rais
recent
studi
highlight
answer
randomis
trial
immunopatholog
studi
address
issu
patient
select
dose
rout
safeti
corticosteroid
andor
antiinflammatori
agent
ongo
bpsu
studi
provid
import
data
regard
current
epidemiolog
caa
rate
mortal
kd
uk
studi
also
need
identifi
biomark
clinic
score
work
outsid
japan
identifi
patient
highest
risk
caa
henc
need
addit
corticosteroid
andor
antitnf
primari
treatment
concert
intern
effort
aim
improv
understand
potenti
infecti
trigger
genet
contribut
kd
diseas
suscept
complic
utmost
import
whether
kd
predispos
prematur
atherosclerosi
correctli
latekd
vasculopathi
subject
ongo
uk
studi
help
provid
evid
base
inform
longterm
manag
strategi
uk
last
signific
challeng
remain
coordin
transit
care
kd
patient
adulthood
uk
current
done
suboptim
develop
local
network
transit
cardiac
care
paediatr
adolesc
adulthood
urgent
requir
conclus
addit
worldwid
effort
understand
genet
kd
time
concert
drive
improv
evid
base
acut
lifelong
manag
import
childhood
diseas
uk
kd
rare
disord
research
improv
understand
aetiolog
pathogenesi
treatment
outcom
requir
multicentr
collabor
exampl
recent
ongo
nation
institut
health
research
nihr
multicentr
studi
kd
uk
contributor
author
involv
draft
articl
revis
critic
import
intellectu
content
author
approv
final
version
publish
proven
peer
review
commiss
extern
peer
review
open
access
open
access
articl
distribut
accord
creativ
common
attribut
non
commerci
cc
bync
licens
permit
other
distribut
remix
adapt
build
upon
work
noncommerci
licens
deriv
work
differ
term
provid
origin
work
properli
cite
use
noncommerci
see
http
creativecommonsorg
